Ayahuasca

The first thing ayahuasca announces is its taste. The brew is thick, dark brown or black, and tastes like nothing you have encountered before -- a dense, earthy bitterness laced with something acrid and vegetal that your body immediately recognizes as powerful. Most people grimace. Some gag on the first swallow. The taste lingers in the mouth like a warning, and your stomach begins responding within minutes -- a deep warmth spreading through the abdomen, heavy and insistent, not pleasant but purposeful.

Within thirty to sixty minutes, nausea arrives in slow, rolling waves. The body knows it has consumed something ancient and pharmacologically serious. Stomach cramps build, a sense of internal pressure mounts, the gut gurgles and churns. For many, the purge comes first -- a vomiting that is not like being sick but like something being pulled out of you. People describe it as releasing grief, rage, years of suppressed emotion, or an illness they did not know they were carrying. The tears that often accompany it feel cleansing in a way ordinary crying does not. Diarrhea is also common and treated with the same matter-of-factness by experienced facilitators. In traditional Amazonian frameworks, this is not a side effect. It is the medicine working.

As the purge subsides -- or sometimes before it -- the visionary dimension opens. It does not arrive gradually like psilocybin's gentle unfolding or slam into existence like smoked DMT. It emerges from darkness behind closed eyelids like a curtain slowly being drawn back. Colors appear with a richness that feels more real than anything produced by ordinary sight. Serpents are almost universally reported -- enormous, luminous, moving with intelligence and intent. Jaguars, geometric mandalas, vast jungle landscapes that seem to breathe, and architectural structures of impossible complexity materialize with startling clarity and autonomous movement. These are not the abstract geometries of synthetic tryptamines or the neon overlays of phenethylamines. They have a narrative quality, a sense of story and meaning, as though you are being shown something specifically for your benefit.

The emotional depth is perhaps ayahuasca's most striking characteristic. Buried memories surface with vivid, embodied intensity -- not as thoughts but as fully re-experienced moments. Grief, love, fear, and joy arrive in waves of shattering force. Many drinkers report reliving pivotal moments of their lives from new perspectives that bring insight and, sometimes, a forgiveness so profound it restructures their understanding of themselves. There is frequently a sense of contact with something much larger than the individual self -- a maternal intelligence, an ecological consciousness, a presence that seems to know you completely and without judgment. The body during this time alternates between complete stillness and waves of somatic release: shaking, sighing, laughing, or weeping.

The peak typically lasts two to four hours, during which you may oscillate between visionary immersion and bodily awareness. Unlike smoked DMT, you remain aware of your body and your surroundings, though they may seem very far away. Icaros -- the ceremonial songs sung by the facilitator -- are not background music but feel like structural elements of the experience, guiding the visions, modulating their intensity, and providing an anchor when the content becomes overwhelming.

The descent is gradual. Visions thin from cinematic narratives to softer, more impressionistic imagery. The body begins to settle. A profound tiredness sets in, but it is not the depleted exhaustion of stimulant comedowns. Instead, there is often a sense of having been emptied and refilled -- cleaned out. The world appears more vivid, more tender, more charged with significance. Sleep that night, when it comes, is often deep and populated with unusually vivid dreams. In the days and weeks that follow, many report lasting emotional clarity, renewed purpose, changed relationships to destructive habits, and a quiet, grounded peace that experienced drinkers call "the afterglow" -- a period of integration that traditional practitioners consider as important as the ceremony itself.

The Synergistic Mechanism

Ayahuasca is a pharmacological duet -- two classes of compounds that are individually unremarkable by the oral route but become profoundly synergistic when combined. The brew traditionally pairs N,N-dimethyltryptamine (DMT), supplied by Psychotria viridis leaves, with beta-carboline alkaloids from the Banisteriopsis caapi vine. Neither component alone accounts for the experience; their interaction is the mechanism.

The MAO Inhibition Gateway

DMT is rapidly degraded by monoamine oxidase-A (MAO-A) in the gut wall and liver, rendering it essentially inactive when swallowed. The beta-carbolines -- harmine,harmaline, andtetrahydroharmine (THH) -- are potent, reversible inhibitors of MAO-A (RIMAs) that shut down this first-pass metabolism. Harmine is the most abundant and most potent of the three, with an IC50 for MAO-A inhibition in the low-nanomolar range. Harmaline is roughly equipotent but present in lower concentrations, while THH is a weaker MAO-A inhibitor but contributes additional serotonin reuptake inhibition . By temporarily disabling the enzymatic barrier, these beta-carbolines allow orally ingested DMT to reach systemic circulation and cross the blood-brain barrier intact. This is why eating Psychotria viridis leaves alone produces no psychedelic effect -- without the vine, DMT never reaches the brain.

Receptor-Level Actions

Once in the brain, DMT acts primarily as an agonist at serotonin 5-HT2A receptors -- the canonical target for classical psychedelic effects. Double-blind experiments using the 5-HT2A antagonist ketanserin have demonstrated near-complete blockade of ayahuasca's subjective and neurophysiological effects, confirming 5-HT2A as the principal mediator of the visionary experience . DMT also engages 5-HT1A receptors (providing an anxiolytic counterbalance), 5-HT2C receptors, dopamine D1 and D2 receptors, andsigma-1 receptors -- the latter implicated in neuroprotection, neuroplasticity, and intracellular calcium signaling. A 2024 study demonstrated that chronic DMT administration alleviated cognitive impairment in Alzheimer's model mice via sigma-1 receptor-mediated restoration of ER-mitochondria crosstalk .

The beta-carbolines themselves are not pharmacologically inert passengers. Harmine and harmaline bind directly to multiple 5-HT receptor subtypes and exhibit agonist activity at 5-HT2A and 5-HT2C, meaning they contribute their own psychoactive and mood-modulating effects alongside DMT. THH's serotonin reuptake inhibition further elevates synaptic serotonin levels, compounding both the psychoactive and the physiological effects of the brew .

The Purge: Gut Serotonin and Emesis

The gastrointestinal tract contains approximately 95% of the body's serotonin, and ayahuasca floods this system from multiple angles -- DMT activates gut 5-HT receptors directly, while MAO inhibition raises ambient serotonin levels throughout the gut. Activation of 5-HT3 receptors in both the GI tract and the brainstem's chemoreceptor trigger zone (area postrema) triggers the emetic reflex . The resulting nausea and vomiting -- "la purga" -- is therefore not a side effect but a direct pharmacological consequence of the brew's serotonergic mechanism, compounded by vagal nerve stimulation from elevated peripheral serotonin. Diarrhea follows a similar pathway via 5-HT4 receptor activation increasing intestinal motility .

Pharmacokinetics

Oral onset occurs 30-60 minutes after ingestion, depending on stomach contents and brew concentration. Plasma DMT levels peak at approximately 90-120 minutes. Total duration is 4-8 hours, substantially longer than smoked DMT (15-30 minutes) because the MAOI component both enables absorption and slows metabolic clearance. The beta-carbolines have their own pharmacokinetic profile -- harmine peaks at approximately 60-90 minutes, with effects lasting several hours beyond DMT clearance, contributing to the gentle, prolonged come-down.

References

Dos Santos RG, Hallak JEC. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neuroscience & Biobehavioral Reviews. 2020;108:423-434. Riba J, et al. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology. 2001;154:85-95. Valle M, et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. European Neuropsychopharmacology. 2016;26(7):1161-1175. Frecska E, et al. The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization. Frontiers in Pharmacology. 2016;7:35. Callaway JC, et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology. 1999;65(3):243-256.

Ancient Roots

The origins of ayahuasca use vanish into Amazonian prehistory. In 2019, researchers analyzing a 1,000-year-old ritual bundle from a rock shelter in southwestern Bolivia -- a leather pouch fashioned from three fox snouts -- identified chemical residues of DMT, harmine, bufotenine, cocaine, and benzoylecgonine. This represents the oldest direct chemical evidence for the combination of DMT and a beta-carboline in an archaeological context, strongly suggesting that ayahuasca-like preparations were known at least by 1000 CE . Ceramic vessels associated with plant-based ritual preparations from the Amazon basin have been tentatively dated earlier, though chemical identification is less definitive. Ethnographic evidence suggests the brew's use may extend back several thousand years across dozens of Indigenous groups spanning Peru, Brazil, Colombia, Ecuador, and Bolivia.

Western Discovery (1851-1908)

European awareness of the brew began with the British plant explorer Richard Spruce, who encountered ayahuasca during his 1851-1854 Amazonian expedition. Spruce collected specimens of Banisteriopsis caapi along the upper Rio Negro of Brazil and meticulously documented its preparation and ceremonial use among the Tukano people. His botanical collection and detailed notes -- not published in full until 1908 -- provided the first scientifically rigorous Western account of the vine and its ritual context . Spruce identified the vine as the key ingredient but could not explain the mechanism behind its psychoactive effects; the pharmacological explanation would not arrive for another century.

The Ethnobotanical Era (1940s-1979)

Richard Evans Schultes, often called the father of modern ethnobotany, transformed the field during over a decade living among Indigenous Amazonian communities beginning in the 1940s. Schultes documented the extraordinary diversity of ayahuasca preparation methods -- different admixture plants, varying ratios, distinct ceremonial contexts -- across dozens of ethnic groups. His work, culminating in the landmark 1979 volume The Plants of the Gods (co-authored with Albert Hofmann, the discoverer of LSD), established ayahuasca as a central pillar of Amazonian ethnopharmacology and demonstrated that Indigenous botanical knowledge constituted a sophisticated pharmacological tradition .

Brazilian Religious Movements (1930s-1986)

In the 1930s, the Brazilian rubber tapper Raimundo Irineu Serra founded theSanto Daime church after experiencing ayahuasca with Indigenous practitioners near the Peruvian border. The church blended Catholicism, African Brazilian spirituality, and Amazonian shamanism, using ayahuasca (called "Daime" -- meaning "give me") as its central sacrament. TheUniao do Vegetal (UDV), established in 1961 byJose Gabriel da Costa, took a more structured, doctrinally formalized approach. Both churches gained legal recognition in Brazil in 1986, when the country's Federal Narcotics Council removed ayahuasca from its list of controlled substances for religious use .

Legal Battles and International Expansion (1999-2006)

As Santo Daime and UDV expanded internationally in the 1990s and 2000s, legal confrontations followed. The landmark case came in 2006, when the U.S. Supreme Court ruled unanimously in Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal that the UDV had a right to use ayahuasca as a religious sacrament under the Religious Freedom Restoration Act. The Netherlands and several other countries subsequently established legal frameworks for religious ayahuasca use. Meanwhile, a separate controversy erupted when the U.S. Patent and Trademark Office granted a patent on the Banisteriopsis caapi vine in 1986 to American Loren Miller -- a patent challenged by the Center for International Environmental Law on behalf of Indigenous organizations, revoked in 1999, reinstated on appeal, and finally allowed to expire in 2003.

Modern Research and Tourism (2010s-Present)

The 21st century has seen two parallel developments. Scientifically, the first randomized controlled trial of ayahuasca for treatment-resistant depression was published in 2019 by Palhano-Fontes et al. at the Federal University of Rio Grande do Norte, demonstrating significant antidepressant effects compared to placebo at one and seven days post-session . Observational studies from UDV and Santo Daime congregations had already documented lower rates of substance abuse, anxiety, and depression among long-term ceremonial users. By 2025, trials were underway for PTSD, alcohol use disorder, and eating disorders. Simultaneously, anayahuasca tourism industry emerged across Peru, Ecuador, Colombia, and Brazil, drawing tens of thousands of international visitors annually. This growth brought legitimate interest in traditional medicine but also serious concerns: cultural appropriation, the commodification of sacred practices, uneven safety standards, sexual abuse by facilitators, and environmental pressure on wild Banisteriopsis caapi populations. Dennis McKenna, ethnopharmacologist and brother of Terence McKenna, has been among the most prominent scientific advocates for both rigorous research and respect for Indigenous intellectual property.

References

Miller MJ, et al. Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. PNAS. 2019;116(23):11207-11212. Spruce R. Notes of a Botanist on the Amazon and Andes. Macmillan, London. 1908. Schultes RE, Hofmann A. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Properties. McGraw-Hill. 1979. Labate BC, Feeney K. Ayahuasca and the process of regulation in Brazil and internationally. International Journal of Drug Policy. 2012;23(2):154-161. Palhano-Fontes F, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine. 2019;49(4):655-663.